[1]赵彩霞,罗显锋,李英淇,等.芍药苷治疗紫癜性肾炎的机制研究进展[J].陕西中医,2026,(3):429.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.028]
　ZHAO Caixia,LUO Xianfeng,LI Yingqi,et al.Research progress on the mechanism of paeoniflorin in the treatment of Henoch-schonlein purpura nephritis[J].,2026,(3):429.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.028]
点击复制

芍药苷治疗紫癜性肾炎的机制研究进展

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年3期
页码:
429
栏目:
综 述
出版日期:
2026-03-05

文章信息/Info

Title:
Research progress on the mechanism of paeoniflorin in the treatment of Henoch-schonlein purpura nephritis
作者:
赵彩霞1; 罗显锋2; 李英淇1; 何平2
（1.云南中医药大学第一临床医学院,云南 昆明 650500;2.云南中医药大学第一附属医院,云南 昆明 650021)
Author(s):
ZHAO Caixia1; LUO Xianfeng2; LI Yingqi1; HE Ping2
(1.The First Clinical Medical College of Yunnan University of Traditional Chinese Medicine，Kunming 650500,China；2.First Affiliated Hospital of Yunnan University of Chinese Medicine，Kunming 650021,China)
关键词:
紫癜性肾炎; IgA血管炎肾病; 芍药苷; 作用机制
Keywords:
Henoch-Schonlein purpura nephritis; IgA vasculitis nephritis; Paeoniflorin; Mechanism of action
分类号:
R 692.34
DOI:
DOI:10.3969/j.issn.1000-7369.2026.03.028
文献标志码:
A
摘要:
紫癜性肾炎（HSPN）是儿童最常见的继发性肾小球疾病，其发病与IgA1异常糖基化、免疫复合物沉积及后续炎症级联反应密切相关。现行免疫抑制疗法存在反应异质性、复发率高及不良反应显著等局限。芍药苷（PF）是毛茛科植物芍药根的核心活性单体，具有抗炎、免疫调节、抗纤维化等多重药理活性。本文系统综述了PF治疗HSPN的分子与细胞机制研究进展。以期为开发 PF成为HSPN新型治疗药物提供一定的理论依据。
Abstract:
Henoch-Schonlein purpura nephritis (HSPN),also known as IgA vasculitis nephritis (IgAVN),is the most common secondary glomerular disease in children.Its pathogenesis is closely associated with aberrantly glycosylated IgA1,immune complex deposition,and subsequent inflammatory cascades.Current immunosuppressive therapies are limited by variable responses,high recurrence rates,and significant side effects.Paeoniflorin (PF),the principal active monoterpene glycoside derived from the roots of Paeonia lactiflora,exhibits multiple pharmacological properties including anti-inflammatory,immunomodulatory,and anti-fibrotic effects.This review systematically summarizes recent advances in the molecular and cellular mechanisms of PF in treating HSPN for providing a solid theoretical foundation for developing PF as a novel therapeutic agent for HSPN.

参考文献/References:

[1]VIVARELLI M,SAMUEL S,COPPO R,et al.IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis[J].Pediatr Nephrol,2025,40(2):533-569.
[2]PARUMS D V.A Review of IgA vasculitis (henoch-schonlein purpura) past,present,and future[J].Med Sci Monit,2024,30:e943912.
[3]ZHONG X,DING J.Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children[J].Pediatr Nephrol,2023,38(6):1707-1715.
[4]HAAS M.IgA vasculitis nephritis:Insights from kidney biopsies[J].Curr Opin Nephrol Hypertens,2024,33(3):298-303.
[5]CAO Y,XIONG J,GUAN X,et al.Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy[J].Phytomedicine,2023,116:154901.
[6]OU X,YU Z,PAN C,et al.Paeoniflorin:A review of its pharmacology,pharmacokinetics and toxicity in diabetes[J].Front Pharmacol,2025,16:1551368.
[7]ZHANG X E,PANG Y B,BO Q,et al.Protective effect of paeoniflorin in diabetic nephropathy:A preclinical systematic review revealing the mechanism of action[J].PLoS One,2023,18(9):e0282275.
[8]TANG X,TAN Y,GAO F,et al.Paeoniflorin attenuates hepatic ischemia-reperfusion injury by modulating Tmem176b macrophages polarization[J].Int Immunopharmacol,2025,167:115657.
[9]邵宽芙蓉,关凤军,董晨.白芍总苷辅助治疗儿童紫癜性肾炎的疗效及其机制探讨:前瞻性随机对照研究[J].中国当代儿科杂志,2021,23(1):49-54.
[10]王一鸣,程燕.白三烯受体拮抗剂联合白芍总苷治疗轻度紫癜性肾炎的临床研究[J].实用医院临床杂志,2019,16(6):202-204.
[11]HU Q,XIE J,JIANG T,et al.Paeoniflorin alleviates DSS-induced ulcerative colitis by suppressing inflammation,oxidative stress,and apoptosis via regulating serum metabolites and inhibiting CDC42/JNK signaling pathway[J].Int Immunopharmacol,2024,142(Pt A):113039.
[12]SONG P,GAO Z,BAO Y,et al.Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy[J].J Hematol Oncol,2024,17(1):46.
[13]MA Q,YU J,ZHANG X,et al.Wnt/β-catenin signaling pathway-a versatile player in apoptosis and autophagy[J].Biochimie,2023,211:57-67.
[14]SAXENA S,DAGAR N,SHELKE V,et al.Wnt/beta-catenin modulation:A promising frontier in chronic kidney disease management[J].Fundam Clin Pharmacol,2024,38(6):1020-1030.
[15]ZHANG J Q,LI Y Y,ZHANG X Y,et al.Cellular senescence of renal tubular epithelial cells in renal fibrosis[J].Front Endocrinol (Lausanne),2023,14:1085605.
[16]付元,刘秀琴,程娜,等.紫癜性肾炎患者外周血单个核细胞Toll样受体3和4的信号转导途径[J].中国组织工程研究,2013,17(53):9182-9188.
[17]李杨,刘冬恋,朱婷婷,等.白芍总苷通过Wnt/β-catenin和TGF-β1/Smad3信号串联干预高尿酸血症肾损害大鼠的作用机制[J].中医药学报,2024,52(12):25-31.
[18]HADPECH S,THONGBOONKERD V.Epithelial-mesenchymal plasticity in kidney fibrosis[J].Genesis,2024,62(1):e23529.
[19]ZHU B,LI F,YU J,et al.PIEZO1 mediates matrix stiffness-induced tumor progression in kidney renal clear cell carcinoma by activating the Ca2＋/Calpain/YAP pathway[J].Biochim Biophys Acta Mol Cell Res,2025,1872(1):119871.
[20]LI R,XIA J,SHI C,et al.Direct pharmacological targeting of piezo1 by paeoniflorin:A novel therapeutic approach for renal fibrosis[J].J Adv Res,2025,25:540-545.
[21]YAN Y,WANG C,LUO S,et al.Lithospermic acid improves diabetic kidney fibrosis by regulating piezo1/TGF-β1/Smad signaling pathway[J].Eur J Pharmacol,2025,1003:177896.
[22]WU D,LEI L,ZHANG H,et al.Clinical relevance of glomerular C4d deposition in children with early IgA nephropathy or Henoch-Schonlein purpura nephropathy[J].Pediatr Nephrol,2023,38(2):431-438.
[23]HUANG Y,LIU C,WEI W,et al.Case report:Atypical anti-GBM nephritis coexisting with Henoch-Schonlein purpura nephritis:Exploring the pathogenic nexus[J].Front Immunol,2025,16:1641090.
[24]ZHANG Y,XU G.IgA vasculitis with nephritis:An overview of the pathogenesis and clinical characteristics[J].Clin Exp Rheumatol,2025,43(4):728-741.

备注/Memo

备注/Memo:
国家自然科学基金资助项目(82160922)
更新日期/Last Update: 2026-03-05